More News! 5 Jan 2017
Investors Jump on Hypersensitivity Peptides from GSK Spinout
Neurokinins are under investigation for a range of conditions from women’s health to pain. NeRRe gets a boost for its programs. Neurotransmitting peptides just got a cash injection from Forbion, Fountain Healthcare Partners, Advent Life Sciences, Novo A/S, and Orbimed. NeRRe Therapeutics, a UK-based spinout of GSK, nailed down a €27M (£23M) Series B round. Helmed by […]
